This development practice evolved into a trend such that drug development was initiated in the USA or Europe, and development in other geographic regions followed in such countries as Japan, South Korea and Taiwan. Development in Canada, Australia, New Zealand, South Africa and South America generally kept pace with development in the USA and Europe. Consequently, throughout the 1980s and early 1990s there was an acknowledged 7 to 10 year ‘drug approval lag’ in Japan, South Korea and Taiwan. Thus, these populations suffered delayed access to new therapies even though safety and efficacy had already been established in other regions of the world. Consequently, it was difficult to explain to the patients residing in these regions why they had to wait so many years beyond the rest of the world to get access to these medications. The urgent need to rationalize and harmonize regulations was understood by regulators worldwide, as well as the global pharmaceutical industry. As a result, ICH E5 – Ethnic Factors in the Acceptability of Foreign Clinical Data (5 Feb 1998) was published and the concept of global clinical development was widely and rapidly adopted.
In recent years, with the rise of global clinical development, Ethnic Bridging in Phase 1 Clinical Trials has become a leading strategy for assessing product sensitivity as it can allow developers to prevent the unnecessary duplication of clinical trials, minimize costs and solve the drug lag issue simultaneously.
Quicker development time means increased valuation of your asset due to the ability to achieve commercial milestones earlier. Watch the webinar recording to hear about specific case studies and strategies on how to include ethnic bridging in your early clinical development plans to hasten regulatory acceptance of data worldwide.